The dopamine metabolite 3-methoxytyramine is a neuromodulator.
dc.contributor.author | Sotnikova, Tatyana D | |
dc.contributor.author | Beaulieu, Jean-Martin | |
dc.contributor.author | Espinoza, Stefano | |
dc.contributor.author | Masri, Bernard | |
dc.contributor.author | Zhang, Xiaodong | |
dc.contributor.author | Salahpour, Ali | |
dc.contributor.author | Barak, Larry S | |
dc.contributor.author | Caron, Marc G | |
dc.contributor.author | Gainetdinov, Raul R | |
dc.contributor.editor | Bartolomucci, Alessandro | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2011-06-21T17:32:17Z | |
dc.date.issued | 2010-10-18 | |
dc.description.abstract | Dopamine (3-hydroxytyramine) is a well-known catecholamine neurotransmitter involved in multiple physiological functions including movement control. Here we report that the major extracellular metabolite of dopamine, 3-methoxytyramine (3-MT), can induce behavioral effects in a dopamine-independent manner and these effects are partially mediated by the trace amine associated receptor 1 (TAAR1). Unbiased in vivo screening of putative trace amine receptor ligands for potential effects on the movement control revealed that 3-MT infused in the brain is able to induce a complex set of abnormal involuntary movements in mice acutely depleted of dopamine. In normal mice, the central administration of 3-MT caused a temporary mild hyperactivity with a concomitant set of abnormal movements. Furthermore, 3-MT induced significant ERK and CREB phosphorylation in the mouse striatum, signaling events generally related to PKA-mediated cAMP accumulation. In mice lacking TAAR1, both behavioral and signaling effects of 3-MT were partially attenuated, consistent with the ability of 3-MT to activate TAAR1 receptors and cause cAMP accumulation as well as ERK and CREB phosphorylation in cellular assays. Thus, 3-MT is not just an inactive metabolite of DA, but a novel neuromodulator that in certain situations may be involved in movement control. Further characterization of the physiological functions mediated by 3-MT may advance understanding of the pathophysiology and pharmacology of brain disorders involving abnormal dopaminergic transmission, such as Parkinson's disease, dyskinesia and schizophrenia. | |
dc.description.version | Version of Record | |
dc.identifier | ||
dc.identifier.eissn | 1932-6203 | |
dc.identifier.uri | ||
dc.language | eng | |
dc.language.iso | en_US | |
dc.publisher | Public Library of Science (PLoS) | |
dc.relation.ispartof | PLoS One | |
dc.relation.isversionof | 10.1371/journal.pone.0013452 | |
dc.relation.journal | Plos One | |
dc.subject | Animals | |
dc.subject | Behavior, Animal | |
dc.subject | Blotting, Western | |
dc.subject | Corpus Striatum | |
dc.subject | Cyclic AMP Response Element-Binding Protein | |
dc.subject | Dopamine | |
dc.subject | Extracellular Signal-Regulated MAP Kinases | |
dc.subject | Humans | |
dc.subject | Mice | |
dc.subject | Mice, Inbred C57BL | |
dc.subject | Mice, Knockout | |
dc.subject | Phosphorylation | |
dc.subject | Signal Transduction | |
dc.title | The dopamine metabolite 3-methoxytyramine is a neuromodulator. | |
dc.title.alternative | ||
dc.type | Journal article | |
duke.date.pubdate | 2010-10-18 | |
duke.description.issue | 10 | |
duke.description.volume | 5 | |
pubs.author-url | ||
pubs.begin-page | e13452 | |
pubs.issue | 10 | |
pubs.organisational-group | Basic Science Departments | |
pubs.organisational-group | Cell Biology | |
pubs.organisational-group | Clinical Science Departments | |
pubs.organisational-group | Duke | |
pubs.organisational-group | Duke Cancer Institute | |
pubs.organisational-group | Duke Institute for Brain Sciences | |
pubs.organisational-group | Institutes and Centers | |
pubs.organisational-group | Institutes and Provost's Academic Units | |
pubs.organisational-group | Medicine | |
pubs.organisational-group | Medicine, Cardiology | |
pubs.organisational-group | Neurobiology | |
pubs.organisational-group | Psychiatry & Behavioral Sciences | |
pubs.organisational-group | Psychiatry & Behavioral Sciences, Translational Neuroscience | |
pubs.organisational-group | School of Medicine | |
pubs.organisational-group | University Institutes and Centers | |
pubs.publication-status | Published online | |
pubs.volume | 5 |